Biomarkers for Tuberous Sclerosis Complex (BioTuScCom)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-08-01

Study Completion Date

2022-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

International, multicenter, observational, longitudinal study to identify biomarker/s for Tuberous Sclerosis Complex and to explore the clinical robustness, specificity, and long´-term variability of these biomarker/s

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Topical Everolimus in Patients With Tuberous Sclerosis Complex

NCT02860494

Facial Angiofibromas

WITHDRAWN PHASE2/PHASE3

Evaluation of SclerFIX Graft in Scleral Thinning After Exeresis of Tumors of the Ocular Surface

NCT05302609

Scleral Thinning

TERMINATED PHASE2

Dermatologic Patterns of Tuberous Sclerosis Patients and Somatic Mutation Relationship

NCT04112537

Tuberous Sclerosis Complex

UNKNOWN

The Scleroderma Biorepository and Pathogenesis Study (STOP Scleroderma)

NCT02887495

Scleroderma

COMPLETED

Analysis of Plasma for Diagnosis and Follow-up of Neurofibromatosis Type 1

NCT02680431

Neurofibromatosis 1

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Tuberous Sclerosis Complex (TSC) is an autosomal dominant genetic disorder characterized by the growth of numerous tumors in different body parts related to dysregulation of the mechanistic target of rapamycin (mTOR) pathway. The overall incidence of TSC is estimated to be as high as 1 in 6000 to 10,000 live birth.The main aspects of TSC that influence the quality of life are associated with the brain: seizures, evelopmental delay, intellectual disability, and autism. However, the incidence and severity of the various aspects of TSC can vary widely.

TSC is generally caused by pathogenic variants in the tumor suppressor genes: TSC1 and TSC2. Confirmation of a clinical diagnosis of tuberous sclerosis is performed via TSC1 and TSC2 sequencing.

There is no cure for TSC, therefore symptomatic therapy is the best possible choice, including mTOR inhibitors, vigabatrin and other antiepileptic drugs for the seizures, and neurosurgery in cases of life-threatening neurological symptoms.

The aim of the study is established TSC specific biomarker/s. Such biomarkers aim to facilitate the diagnosis, treatment personalization and monitoring.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypomelanotic Macules Facial Angiofibroma Shagreen Patches Ungual Fibromas Cortical Dysplasia Cardiac Rhabdomyoma Lymphangioleiomyomatosis Renal Angiomyolipoma Subependymal Giant Cell Astrocytoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants with Tuberous Sclerosis Complex (TSC)

Üarticipants diagnosed with Tuberous Sclerosis Complex (TSC) aged between 2 months and 50 years.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Informed consent is obtained from the participant or from the parent / legal guardian
* Participant is aged between 2 and 50 years
* Diagnosis of TSC is genetically confirmed by CENTOGENE

Exclusion Criteria

* Inability to provide informed consent
* Participant is younger than 2 or older than 50 years
* Diagnosis of TSC is not genetically confirmed by CENTOGENE

Minimum Eligible Age

2 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No